Tag: 1

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Allied Properties REIT (“Allied”) (TSX:AP.UN) announced today that the Trustees of Allied have declared a distribution of $0.15 per unit for the month of August 2025, representing $1.80 per unit on an annualized basis. The distribution will be payable on September 15, 2025, to unitholders of record as at August 29, 2025.

OTTAWA, Ontario, 15 août 2025 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne lance un appel aux dons au profit du Fonds de secours : Feux de forêt de 2025 à Terre-Neuve-et-Labrador afin de venir en aide aux personnes et aux communautés éprouvées par les incendies qui brûlent dans la province.

OTTAWA, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the 2025 Newfoundland & Labrador Wildfires Appeal to help people and communities impacted by fires in the province.

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Fly-E Group, Inc. (Nasdaq: FLYE) (“Fly-E” or the “Company”), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters, today announced the grand opening of its newest retail location in Boston, Massachusetts. The new store, now fully operational, marks the Company’s continued expansion in the Northeastern United States and underscores its mission to make safe, reliable, and eco-friendly transportation accessible to more communities.

Landmark listing makes Kyivstar the first and only publicly listed pure-play Ukrainian investment opportunity in the U.S. Stock Markets

CINCINNATI, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reported financial results for the second quarter ended June 30, 2025.

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile